| P50 | author | Hans Guenter Drexler | Q66431272 |
| | Hilmar Quentmeier | Q92502255 |
| | Monika Prochorec-Sobieszek | Q104802863 |
| | Andrew L Feldman | Q42397592 |
| | Rhett P. Ketterling | Q46177716 |
| P2093 | author name string | Marshall E Kadin | |
| | Robert Geffers | |
| | Corinna Meyer | |
| | Maren Kaufmann | |
| | Stefan Nagel | |
| | Björn Schneider | |
| | Roderick A F MacLeod | |
| | Ryan A Knudson | |
| | Stefan Ehrentraut | |
| | Michaela E Scherr | |
| P2860 | cites work | Genetic Reprogramming of Primary Human T Cells Reveals Functional Plasticity in Th Cell Differentiation | Q52005548 |
| | Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. | Q54581202 |
| | Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2 | Q57054898 |
| | The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3 | Q58483483 |
| | Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction | Q77993656 |
| | A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma | Q82314612 |
| | Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target? | Q83359264 |
| | Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia | Q84815142 |
| | Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? | Q37998574 |
| | In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. | Q38309092 |
| | Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders | Q39455159 |
| | Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway | Q39586865 |
| | SOCS2: inhibitor of JAK2V617F-mediated signal transduction | Q39943570 |
| | Cytogenetic harvesting of commonly used tumor cell lines | Q40150005 |
| | JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders | Q40330808 |
| | SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation | Q40366547 |
| | The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression | Q40422320 |
| | Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. | Q40477164 |
| | Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. | Q40649450 |
| | Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells | Q40758375 |
| | Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells | Q40895260 |
| | Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling | Q40949830 |
| | Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone | Q41628370 |
| | JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin | Q24318979 |
| | Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling | Q24532238 |
| | Janus kinase deregulation in leukemia and lymphoma | Q26991810 |
| | Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism | Q28203313 |
| | Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia | Q28250886 |
| | A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia | Q28253771 |
| | SOCS2 negatively regulates growth hormone action in vitro and in vivo | Q28508170 |
| | Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci | Q28924378 |
| | STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma | Q31835214 |
| | Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis | Q33393587 |
| | JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths | Q33399347 |
| | Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes | Q33889476 |
| | JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients | Q33971316 |
| | Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation | Q34245259 |
| | From the cradle to the grave: activities of GATA‐3 throughout T‐cell development and differentiation | Q34248553 |
| | The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors | Q34754412 |
| | SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses. | Q35102288 |
| | Loss of receptors for transforming growth factor beta in human T-cell malignancies. | Q35546848 |
| | Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity | Q35822851 |
| | SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function | Q36525983 |
| | SOCS regulation of the JAK/STAT signalling pathway | Q37003892 |
| | Human leukemia and lymphoma cell lines as models and resources | Q37090024 |
| | The many faces of the SOCS box. | Q37307127 |
| | PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms | Q37810947 |
| | The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma | Q37975058 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e53767 | |
| P577 | publication date | 2013-01-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. | |
| P478 | volume | 8 | |